Compare BTQ & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTQ | BBOT |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.8M | 1.1B |
| IPO Year | N/A | N/A |
| Metric | BTQ | BBOT |
|---|---|---|
| Price | $5.49 | $12.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.00 | ★ $23.80 |
| AVG Volume (30 Days) | ★ 3.1M | 194.2K |
| Earning Date | 03-25-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $405,988.00 | N/A |
| Revenue This Year | $100.70 | N/A |
| Revenue Next Year | $669.96 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 35.72 | N/A |
| 52 Week Low | $0.95 | $8.50 |
| 52 Week High | $16.00 | $14.87 |
| Indicator | BTQ | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
BTQ Technologies Corp is engaged in the development of computer-based technology related to post-quantum cryptography, particularly as it applies to blockchain and related technologies, and their protection from the emerging security risk of quantum computing. Its products include PQScale, Keelung, Kenting, and Qbyte. PQScale is a novel scaling technique for post-quantum cryptographic primitives. Keelung is a zero-knowledge toolkit for fast, private, and secure applications. Kenting provides acceleration for NIST-compliant post-quantum cryptography, post-quantum zk-SNARKs, and eco-friendly mining hardware, and Qbyte is a quantum risk calculator. Geographically, the company derives maximum revenue from Canada, and also has a presence in Taiwan, and Australia.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.